Alaunos Therapeutics Inc. is a clinical-stage biopharmaceutical company headquartered in Houston, Texas, dedicated to advancing innovative immuno-oncology therapies for cancer treatment. With a strong focus on developing its proprietary T Cell Receptor (TCR) therapy platform, Alaunos aims to harness the power of the immune system to provide effective, targeted therapies for patients with solid tumors. As it continues to progress through clinical trials, the company is positioned to play a significant role in the evolving landscape of cancer therapeutics, potentially offering new hope to patients facing challenging diagnoses.